James McNair, MD
Ophthalmology · Heber Springs, ARNPI 1902887003
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $483 and has fallen 68.4% since, to $152 in 2025.
Across 69 payments — averaging $29.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$242
- Sun Pharmaceutical Industries Inc.$237
- Aerie Pharmaceuticals, Inc.$228
- Kala Pharmaceuticals, Inc.$211
- Amgen$151
- AbbVie$136
- plus $842 from 14 others
What the payments were for
- Food & beverage$2,045100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $242 |
| Sun Pharmaceutical Industries Inc. | 8 | $237 |
| Aerie Pharmaceuticals, Inc. | 8 | $228 |
| Kala Pharmaceuticals, Inc. | 1 | $211 |
| Amgen | 2 | $151 |
| AbbVie(2 entities) | 7 | $136 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $135 |
| Alcon | 4 | $119 |
| Dompe US, Inc. | 4 | $115 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $113 |
| Eyevance Pharmaceuticals LLC | 4 | $82 |
| Ocular Therapeutix, Inc. | 4 | $67 |
| Bausch & Lomb Americas Inc. | 3 | $60 |
| Oyster Point Pharma, Inc. | 2 | $40 |
| Harrow Eye, LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Omeros Corporation | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVELTYS$211
- TEPEZZA$125
- Rhopressa$125
- Rocklatan$125
- Tecnis Multifocal Family of 1-piece IOLS$113
How this compares
$2,045 in reported general payments places this provider in the 75th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 212 | $74,343 |
| Lotemax SmLoteprednol Etabonate | 262 | $66,640 |
| RhopressaNetarsudil Mesylate | 98 | $52,884 |
| LumiganBimatoprost | 64 | $31,128 |
| Ketorolac Tromethamine | 478 | $23,335 |
| MoxifloxacinMoxifloxacin Hcl | 539 | $18,829 |
| Prednisolone Acetate | 332 | $16,296 |
| VyzultaLatanoprostene Bunod | 30 | $13,960 |
| Alphagan PBrimonidine Tartrate | 33 | $13,774 |
| XiidraLifitegrast | 12 | $13,703 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 526 | $6,923 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $5,577 |
| Latanoprost | 355 | $5,381 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 66 | $3,429 |
| Travoprost | 15 | $2,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $135 | $140,983474 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $228 | $52,88498 claims |
| AbbVieLumigan, Alphagan P | $136 | $44,90397 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $60 | $27,66342 claims |
| AlconSimbrinza | $119 | $5,57724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 125 ophthalmology providers in Arkansas.
Other ophthalmology in Heber Springs
- Daniel SinesRogers$81K
- Mike McFarlandPine Bluff$63K
- Jennifer DoyleLittle Rock$38K
- James LinderMarion$18K
- Matthew MargolisJonesboro$17K
- Thomas StankJonesboro$16K
- Andrew PerinNorth Little Rock$4K
- Jeffrey HoltHot Springs$4K
- Joshua LittleJonesboro$4K
- Jonathan CascianoLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.